We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PerkinElmer Launches Its New Imaging System

 PerkinElmer Launches Its New Imaging System content piece image

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of " PerkinElmer Launches Its New Imaging System"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

 PerkinElmer, Inc announced the launch of its Vectra® Polaris™ Automated Quantitative Pathology Imaging System.  This new multi-modal tissue imaging system enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches.

The Vectra Polaris system integrates high throughput, seven-color multispectral imaging with whole-slide scanning in a simplified digital pathology workflow to support the quantification and analysis of tissue sections that are stained with multiple immunohistochemical stains. This helps scientists assess biomarkers that probe deeper into the biology occurring in the immune system and cancer by detecting multiple cell types and their functional states, while also allowing researchers to determine their spatial distributions.

“From basic research to clinical research studies, scientists continue to seek advanced imaging technologies to better analyze and understand disease mechanisms,” said Jim Corbett, Executive Vice President and President, Discovery & Analytical Solutions, PerkinElmer. “The Vectra Polaris system is an innovative solution that helps further the exploration of new cancer immunotherapy approaches to help unlock the promise of precision medicine.”

The Vectra Polaris system is part of PerkinElmer's Phenoptics workflow solution for quantitative pathology research, which enables exploration of the interaction between tumours and immune cells to obtain a deeper understanding of disease mechanisms.

“PerkinElmer's multiplex IHC platform has addressed a critical need in immuno-oncology research to reveal the cell-level biology occurring in the tumour and its microenvironment that drives disease progression and response to immunotherapy,” said Dr. Bernard A. Fox, PhD, Chief, Laboratory of Molecular and Tumour Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center (Oregon).

“The development of the Vectra Polaris system has come at the right time, to support the transition from an exploratory research tool to a high throughput rugged high speed slide analysis research system that overlays PerkinElmer's unique multispectral technology on to a digital pathology workflow.  I believe the Vectra technology will become the standard for tissue biomarker studies in immuno-oncology research and form the basis for tailoring cancer therapies of the future. '

This article has been republished from materials provided by Perkin Elemer. Note: material may have been edited for length and content. For further information, please contact the cited source.